You have free access to this content

Cancer

Cover image for Cancer

1 January 2008

Volume 112, Issue 1

Pages 1–222

  1. Editorials

    1. Top of page
    2. Editorials
    3. Review Article
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
  2. Review Article

    1. Top of page
    2. Editorials
    3. Review Article
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
      Monitoring of minimal residual disease in acute myeloid leukemia (pages 4–16)

      Wolfgang Kern, Claudia Haferlach, Torsten Haferlach and Susanne Schnittger

      Article first published online: 13 NOV 2007 | DOI: 10.1002/cncr.23128

      By using all available markers, including NPM1 mutations and FLT3 mutations in addition to fusion genes, real-time quantitative polymerase chain reaction-based assessment of minimal residual disease is possible in more than half of patients, whereas multiparameter flow cytometry is applicable to most acute myeloid leukemia cases.

  3. Original Articles

    1. Top of page
    2. Editorials
    3. Review Article
    4. Original Articles
    5. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy (pages 17–26)

      Jeon Hor Chen, Byon Feig, Garima Agrawal, Hon Yu, Philip M. Carpenter, Rita S. Mehta, Orhan Nalcioglu and Min Ying Su

      Article first published online: 13 NOV 2007 | DOI: 10.1002/cncr.23130

      Magnetic resonance imaging may predict a pathologically complete response with high accuracy in breast cancer patients who are HER-2 positive, but it has a high false-negative rate in HER-2 negative patients, particularly in patients who are receiving antiangiogenic agents.

    2. You have free access to this content
      Statin use and risk of breast cancer (pages 27–33)

      Gaia Pocobelli, Polly A. Newcomb, Amy Trentham-Dietz, Linda Titus-Ernstoff, John M. Hampton and Kathleen M. Egan

      Article first published online: 15 NOV 2007 | DOI: 10.1002/cncr.23129

      In this population-based case-control study, breast cancer cases (n = 3859) were not more likely than controls (n = 4761) to have ever used statins (odds ratio [OR], 1.0; 95% confidence interval [CI], 0.8–1.2). Ever use of fluvastatin was associated with a decreased risk of breast cancer (OR, 0.5; 95% CI, 0.3–0.8), but the magnitude of the ORs did not vary across categories of duration of use.

    3. Gastrointestinal Disease
      You have free access to this content
      Improved survival with adjuvant external-beam radiation therapy in lymph node-negative pancreatic cancer : A United States population-based assessment (pages 34–42)

      Avo Artinyan, Minia Hellan, Pablo Mojica-Manosa, Yi-Jen Chen, Richard Pezner, Joshua D. I. Ellenhorn and Joseph Kim

      Article first published online: 13 NOV 2007 | DOI: 10.1002/cncr.23134

      Adjuvant external-beam radiation therapy was associated with improved survival in patients with operable, lymph node-negative pancreatic cancer. These findings suggest that adjuvant radiation therapy should be considered for all patients with locally confined, lymph node-negative pancreatic cancer.

    4. You have free access to this content
      Hypermethylation of the somatostatin promoter is a common, early event in human esophageal carcinogenesis (pages 43–49)

      Zhe Jin, Yuriko Mori, James P. Hamilton, Alexandru Olaru, Fumiaki Sato, Jian Yang, Tetsuo Ito, Takatsugu Kan, Rachana Agarwal and Stephen J. Meltzer

      Article first published online: 12 NOV 2007 | DOI: 10.1002/cncr.23135

      Both somatostatin methylation frequency and normalized methylation values were significantly higher in Barrett metaplasia (BE), low-grade and high-grade dysplasia occurring in BE, esophageal adenocarcinomas, and esophageal squamous cell carcinomas than in normal esophageal mucosa. Somatostatin promoter hypermethylation is a common event in human esophageal carcinomas and is related to early neoplastic progression in the esophagus.

    5. You have free access to this content
      Prognostic significance of mesenteric tumor nodules in patients with stage III colorectal cancer (pages 50–54)

      Dorothy S. Lo, Aaron Pollett, Lillian L. Siu, Steve Gallinger and Ronald L. Burkes

      Article first published online: 15 NOV 2007 | DOI: 10.1002/cncr.23136

      A retrospective review is presented of 786 patients with stage III colorectal cancer, of whom 116 (14.8%) had mesenteric tumor nodules in their surgical specimens. In comparison to SEER survival data, the presence of mesenteric nodules appears to worsen the prognosis of any T/N0 disease to that of overall stage III disease. Mesenteric nodules with any T/N1+ disease had prognosis similar to that of stage IIIC disease, but the prognosis was better than M1 disease.

    6. Genitourinary Disease
      You have free access to this content
      The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer (pages 55–60)

      Matthew C. Abramowitz, Tiaynu Li, Mark K. Buyyounouski, Eric Ross, Robert G. Uzzo, Alan Pollack and Eric M. Horwitz

      Article first published online: 29 OCT 2007 | DOI: 10.1002/cncr.23139

      The objective of the current study was to compare the American Society for Therapeutic Radiology and Oncology (ASTRO) and Phoenix (Nadir + 2 ng/mL) biochemical failure (BF) estimates as determinants of distant metastasis, cause-specific mortality, and overall mortality (OM). The authors demonstrate that the Phoenix definition of BF is a more robust determinant of patient outcome including OM, compared with the ASTRO definition.

    7. You have free access to this content
      Treatment ‘mismatch’ in early prostate cancer : Do treatment choices take patient quality of life into account? (pages 61–68)

      Ronald C. Chen, Jack A. Clark, Judith Manola and James A. Talcott

      Article first published online: 26 NOV 2007 | DOI: 10.1002/cncr.23138

      Relevant pretreatment dysfunction does not appear to reliably influence treatment choices for early prostate cancer, and patients receiving relatively contraindicated (‘mismatched’) treatments had worse outcomes. Further study is needed to determine why mismatched treatments were chosen, and whether using a validated questionnaire before treatment decision-making could improve communication and thus outcomes.

    8. You have free access to this content
      Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent (pages 69–74)

      Michael W. Kattan, Jack Cuzick, Gabrielle Fisher, Daniel M. Berney, Tim Oliver, Christopher S. Foster, Henrik Møller, Victor Reuter, Paul Fearn, James Eastham and Peter T. Scardino

      Article first published online: 13 NOV 2007 | DOI: 10.1002/cncr.23106

      An accurate tool was developed for predicting the probability that a man with clinically localized prostate cancer will survive his disease for 120 months if the cancer is not treated with curative intent immediately. The tool should be helpful for patient counseling and clinical trial design.

    9. You have free access to this content
      Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer : A multi-institutional, long-term experience (pages 75–83)

      Sisto Perdonà, Riccardo Autorino, Rocco Damiano, Marco De Sio, Brunello Morrica, Luigi Gallo, Giustino Silvestro, Antonio Farella, Sabino De Placido and Giuseppe Di Lorenzo

      Article first published online: 15 NOV 2007 | DOI: 10.1002/cncr.23137

      Conservative combined treatment is a reasonable alternative to radical cystectomy in selected patients with muscle-invasive bladder cancer.

    10. Gynecologic Oncology
      You have free access to this content
      Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma (pages 84–93)

      Hiep Phuc Dong, Lilach Kleinberg, Ilvars Silins, Vivi Ann Flørenes, Claes G. Tropé, Björn Risberg, Jahn M. Nesland and Ben Davidson

      Article first published online: 5 NOV 2007 | DOI: 10.1002/cncr.23140

      Death receptors are coexpressed in ovarian carcinoma cells in effusions. Higher expression of death receptors is associated with more advanced FIGO stage, poor response to chemotherapy, and poor progression-free and overall survival.

    11. Head and Neck
      You have free access to this content
      Salvage therapy in relapsed squamous cell carcinoma of the oral cavity: How and when? (pages 94–103)

      Chun-Ta Liao, Joseph Tung-Chieh Chang, Hung-Ming Wang, Shu-Hang Ng, Chuen Hsueh, Li-Yu Lee, Chih-Hung Lin, I-How Chen, Shiang-Fu Huang, Ann-Joy Cheng and Tzu-Chen Yen

      Article first published online: 16 NOV 2007 | DOI: 10.1002/cncr.23142

      Among patients with relapsed squamous cell carcinoma of the oral cavity (OSCC), a late relapse was associated with better survival than a relapse within the first 10 months after initial treatment. The authors concluded that patients with OSCC who have a late relapse may benefit from salvage therapy. Among patients with OSCC who have an early relapse, salvage therapy should be considered for those who have a primary tumor depth <10 mm.

    12. You have free access to this content
      Expression of hepatocyte growth factor and c-MET in skull base chordoma (pages 104–110)

      Takahiko Naka, Doerthe Kuester, Carsten Boltze, Stefanie Scheil-Bertram, Amir Samii, Christian Herold, Helmut Ostertag, Sabine Krueger and Albert Roessner

      Article first published online: 19 OCT 2007 | DOI: 10.1002/cncr.23141

      In the current study, c-MET expression was a common event in skull base chordoma. It was found to be correlated with the expression of low molecular weight cytokeratin (CAM5.2), younger patient age, and a favorable prognosis.

    13. You have free access to this content
      Outcomes after radiotherapy for squamous cell carcinoma of the eyelid (pages 111–118)

      Janjira Petsuksiri, Steven J. Frank, Adam S. Garden, K. Kian Ang, William H. Morrison, K. S. Clifford Chao, David I. Rosenthal, David L. Schwartz, Anesa Ahamad and Bita Esmaeli

      Article first published online: 26 OCT 2007 | DOI: 10.1002/cncr.23143

      Primary radiotherapy for squamous cell carcinoma of the eyelid produces high control rates with good function and cosmesis and should be considered an alternative to surgery in selected patients. Given the low incidence of isolated regional metastasis in this series, routine prophylactic treatment of the regional lymph nodes is not recommended.

    14. Hematologic Malignancies
      You have free access to this content
      Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia (pages 119–128)

      Giovanni Del Poeta, Maria Ilaria Del Principe, Francesco Buccisano, Luca Maurillo, Giovanni Capelli, Fabrizio Luciano, Alessio Pio Perrotti, Massimo Degan, Adriano Venditti, Paolo de Fabritiis, Valter Gattei and Sergio Amadori

      Article first published online: 12 NOV 2007 | DOI: 10.1002/cncr.23144

      Consolidation and maintenance therapy with rituximab in 28 patients with untreated B-cell chronic lymphocytic leukemia (B-CLL) in complete remission (CR) or partial remission (PR) who were positive for minimal residual disease (MRD) allowed them to achieve a longer response duration (87% vs 32% at 5 years; P = .001) compared with a subset of patients who did not receive consolidation and were positive for MRD (n = 18 patients). Moreover, within the ZAP-70-positive subset (n = 35 patients) and considering only patients who were positive for MRD (n = 23 patients), a longer response duration (69% vs 0% at 2.6 years; P = .007) was observed in the consolidated patients (n = 12) compared with the unconsolidated patients (n = 11).

    15. You have free access to this content
      Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma : Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone (pages 129–135)

      Ulf-Henrik Mellqvist, Stig Lenhoff, Hans E. Johnsen, Martin Hjorth, Erik Holmberg, Gunnar Juliusson, Jon Magnus Tangen and Jan Westin

      Article first published online: 31 OCT 2007 | DOI: 10.1002/cncr.23145

      Combined vincristine, doxorubicin, and dexamethasone (VAD) usually has been the initial therapy for patients with myeloma before high-dose therapy and autologous stem cell transplantation. The results from this prospective, randomized, multicenter study indicated that cyclophosphamide plus dexamethasone was relatively atoxic and was as effective as VAD as initial therapy.

    16. Lung Disease
      You have free access to this content
      Survival improvements for advanced stage nonbronchioloalveolar carcinoma-type nonsmall cell lung cancer cases with ipsilateral intrapulmonary nodules (pages 136–143)

      Jason A. Zell, S.-H. Ignatius Ou, Argyrios Ziogas and Hoda Anton-Culver

      Article first published online: 25 OCT 2007 | DOI: 10.1002/cncr.23146

      Stage IIIB and stage IV nonsmall cell lung cancer (NSCLC) patients with ipsilateral intrapulmonary nodules have improved survival outcomes compared with other patients with stage IIIB and IV disease. The results of the current study add further support for modifications to the current staging system for NSCLC.

    17. Melanoma
      You have free access to this content
      Osteopontin as a molecular prognostic marker for melanoma (pages 144–150)

      Javier Rangel, Mehdi Nosrati, Sima Torabian, Ladan Shaikh, Stanley P. L. Leong, Chris Haqq, James R. Miller III, Richard W. Sagebiel and Mohammed Kashani-Sabet

      Article first published online: 19 NOV 2007 | DOI: 10.1002/cncr.23147

      Previous studies have suggested a role for osteopontin as a marker of disease progression in patients with melanoma. In the current study, the authors describe osteopontin as an independent prognostic marker in patients with cutaneous melanoma and discuss its novel role for predicting melanoma lymph node metastasis.

    18. Neuro-Oncology
      You have free access to this content
      Bcl-6 predicts improved prognosis in primary central nervous system lymphoma (pages 151–156)

      Oren Levy, Lisa M. DeAngelis, Daniel A. Filippa, Katherine S. Panageas and Lauren E. Abrey

      Article first published online: 12 NOV 2007 | DOI: 10.1002/cncr.23149

      In this study, the authors evaluated the value of B-cell differentiation markers in 66 patients with primary central nervous system lymphoma. Most tumors were categorized best as having a nongerminal center phenotype, and bcl-6 was identified as a positive prognostic marker.

    19. You have free access to this content
      The first score predicting overall survival in patients with metastatic spinal cord compression (pages 157–161)

      Dirk Rades, Juergen Dunst and Steven E. Schild

      Article first published online: 19 OCT 2007 | DOI: 10.1002/cncr.23150

      In the current study, the authors present a scoring system that allows for the adequate prediction of survival ≥6 months after radiotherapy in patients with metastatic spinal cord compression. The scoring system is based on 6 significant prognostic factors obtained from an analysis of 1852 patients.

    20. Discipline

      Cancer Disparities
      You have free access to this content
      Racial differences in pain during 1 year among women with metastatic breast cancer : A hazards analysis of interval-censored data (pages 162–170)

      Liana D. Castel, Benjamin R. Saville, Venita DePuy, Paul A. Godley, Katherine E. Hartmann and Amy P. Abernethy

      Article first published online: 26 NOV 2007 | DOI: 10.1002/cncr.23133

      Worsening pain outcomes were studied during the course of 1 year by using hazard models to identify baseline and time-dependent clinical and demographic risk factors associated with differences in pain severity and interference. There were statistically significant differences by race in risks for worsening pain over the course of metastatic disease. Earlier intervention and more aggressive pain management in at-risk subgroups are recommended.

    21. You have free access to this content
      Racial and ethnic differences in breast cancer survival : How much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? (pages 171–180)

      Elana Curtis, Chris Quale, David Haggstrom and Rebecca Smith-Bindman

      Article first published online: 26 NOV 2007 | DOI: 10.1002/cncr.23131

      The study found large differences by race/ethnicity (R/E) in breast cancer survival for elderly women; screening mammography, tumor severity, biology, treatment, comorbidities, and demographics all contributed to these differences. Controlling for these predictor variables reduced nearly all of the differences between African American and white women in the all stages analysis and reduced, but did not eliminate, disparities when the analysis was limited to those women with stage II/III disease.

    22. You have free access to this content
      Cancer in Appalachia, 2001–2003 (pages 181–192)

      Phyllis A. Wingo, Thomas C. Tucker, Patricia M. Jamison, Howard Martin, Colleen McLaughlin, Rana Bayakly, Susan Bolick-Aldrich, Pat Colsher, Robert Indian, Karen Knight, Stacey Neloms, Reda Wilson and Thomas B. Richards

      Article first published online: 13 NOV 2007 | DOI: 10.1002/cncr.23132

      Overall, cancer rates were higher in Appalachia than in the rest of the US; the rates of lung and colon/rectum cancers were particularly high. Cancer rates varied significantly between the 3 regions of Appalachia.

    23. Pathology
      You have free access to this content
      Metastases to soft tissue : A review of 118 cases over a 30-year period (pages 193–203)

      Jose Antonio Plaza, Delia Perez-Montiel, Joel Mayerson, Carl Morrison and Saul Suster

      Article first published online: 26 NOV 2007 | DOI: 10.1002/cncr.23151

      Metastatic tumors presenting as soft tissue masses are relatively rare and can be the source of diagnostic difficulties. The authors' experience at a large academic medical center is reviewed over a 30-year period. Overall, 118 cases of metastases to soft tissues were identified, the majority of which corresponded to metastatic carcinomas from internal organs. Use of immunohistochemistry was useful for distinguishing metastatic carcinoma with sarcomatoid features from a primary sarcoma.

    24. Symptom Control and Palliative Care
      You have free access to this content
      Comparison of the efficacy and safety of miconazole 50-mg mucoadhesive buccal tablets with miconazole 500-mg gel in the treatment of oropharyngeal candidiasis : A prospective, randomized, single-blind, multicenter, comparative, phase III trial in patients treated with radiotherapy for head and neck cancer (pages 204–211)

      Rene-Jean Bensadoun, Jamel Daoud, Brahim El Gueddari, Laurent Bastit, Rene Gourmet, Andrzej Rosikon, Christophe Allavena, Philippe Céruse, Gilles Calais and Pierre Attali

      Article first published online: 28 NOV 2007 | DOI: 10.1002/cncr.23152

      The objective of this study was to compare 50-mg miconazole mucoadhesive buccal tablets (MBT) (Loramyc) with 500-mg miconazole oral gel (MOG) as first-line therapy for oropharyngeal candidiasis (OPC) in patients with head and neck cancer. The results indicated that MBT was not significantly inferior to MOG in the treatment of cancer patients with OPC; and, after adjusting for prognostic variables, it was more effective than MOG. MBT was tolerated well and, thus, may be recommended as first-line treatment in cancer patients with OPC as an alternative to systemic antifungal agents.

    25. Translational Research
      You have free access to this content
      Overcoming barriers to cancer clinical trial accrual : Impact of a mass media campaign (pages 212–219)

      Ari Umutyan, Christine Chiechi, Laurel A. Beckett, Debora A. Paterniti, Corinne Turrell, David R. Gandara, Sharon W. Davis, Ted Wun, Moon S. Chen Jr. and Primo N. Lara Jr.

      Article first published online: 15 NOV 2007 | DOI: 10.1002/cncr.23170

      The authors sought to increase awareness of cancer clinical trials (CCT) and of a new law that required all insurers to reimburse costs related to CCT through a mass multimedia campaign (MMC) in the catchment area of the University of California Davis Cancer Center. They assessed willingness to participate in and accrual to CCT. The results indicated that awareness increased significantly after the MMC, although it was unclear whether the increase was attributable entirely to the MMC or to varying demographic variables.

  4. Correspondence

    1. Top of page
    2. Editorials
    3. Review Article
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content

SEARCH

SEARCH BY CITATION